Liraglutide treatment reduced diabetic kidney damage in rats by downregulating KLF5, autotaxin, and the lysophosphatidic acid signaling axis involved in kidney fibrosis.
KLF5, autotaxin, and PCNA all reducedLiraglutide suppressed three key proteins in the lysophosphatidic acid kidney damage pathway, suggesting it works upstream through KLF5 to shut down the entire cascade
What the researchers found
In streptozotocin/high-fat-diet diabetic rats, 21 days of liraglutide treatment (200 μg/kg/day subcutaneous) produced multiple renoprotective effects: decreased serum biomarkers of diabetic nephropathy, reduced histological abnormalities in kidney tissues, and decreased protein expression of three key molecules in the lysophosphatidic acid (LPA) axis — PCNA (a cell proliferation marker), autotaxin (the enzyme that produces LPA), and KLF5 (the transcription factor that regulates autotaxin expression).
The downregulation of all three components suggests liraglutide works upstream through KLF5 to suppress the entire LPA signaling cascade that drives kidney fibrosis and damage in diabetes.
Why it matters
Diabetic nephropathy is the leading cause of kidney failure worldwide, affecting about 40% of diabetic patients. While GLP-1 drugs are known to have kidney-protective effects in clinical trials, the molecular mechanisms have been unclear. This study identifies a specific pathway — the KLF5-autotaxin-LPA axis — that liraglutide modulates, which could lead to more targeted therapies for diabetic kidney disease and help identify which patients are most likely to benefit from GLP-1 treatment.
How the study worked
Wistar albino rats were divided into four groups: nondiabetic control, liraglutide-treated nondiabetic, diabetic control, and liraglutide-treated diabetic. Diabetes was induced with intraperitoneal streptozotocin (30 mg/kg) combined with a high-fat diet. Control groups received normal saline for 42 days. Treatment groups received saline for 21 days followed by liraglutide (200 μg/kg/day subcutaneous) for 21 days. Outcomes included serum diabetic nephropathy biomarkers, kidney histology, and protein expression analysis of PCNA, autotaxin, and KLF5.
What this study cannot tell us
This is an animal study using a chemically-induced diabetes model (streptozotocin), which doesn't perfectly replicate human type 2 diabetes. The treatment duration of only 21 days is short for a chronic condition like diabetic nephropathy. The study doesn't clarify whether liraglutide's kidney effects are independent of its blood sugar lowering — some of the observed benefits could be secondary to improved glycemic control. Specific quantitative data for the biomarker and protein expression changes are not reported in the abstract.
How to read the evidence
This is a preclinical animal study using a standard diabetes rat model. While it provides valuable mechanistic insight into how GLP-1 drugs protect kidneys, the evidence is early-stage and limited by the use of a chemically-induced diabetes model and short treatment duration. Clinical relevance depends on validation in human kidney tissue or clinical studies.
When this study was published
Published in 2024, this is a very recent study adding mechanistic understanding to the clinically established kidney-protective effects of GLP-1 receptor agonists.
The bigger picture
Clinical trials like LEADER and SUSTAIN-6 have shown that GLP-1 receptor agonists protect the kidneys in diabetic patients, but the mechanisms have remained debated — is it simply better blood sugar control, weight loss, and blood pressure reduction? Studies like this point to direct molecular effects, specifically the modulation of lipid signaling pathways in kidney tissue. Understanding these mechanisms could lead to combination therapies that enhance kidney protection beyond what GLP-1 drugs achieve alone.
Questions still open
- Does liraglutide's kidney protection through the KLF5-LPA axis occur independently of its blood sugar lowering effects?
- Could directly targeting the autotaxin-LPA pathway with specific inhibitors provide even greater kidney protection than GLP-1 drugs alone?
- Do the kidney-protective effects of other GLP-1 agonists like semaglutide work through the same KLF5-mediated mechanism?
Common questions
How does diabetes damage the kidneys?
Does this mean liraglutide can prevent kidney failure in diabetic patients?
Read the original research
Renoprotective effect of liraglutide on diabetic nephropathy by modulation of Krüppel-like transcription factor 5 expression in rats.
The Journal of pharmacy and pharmacology, 76(12), 1563-1571
Citation
Bin Dayel, Anfal F; Alrasheed, Nouf M; Alonazi, Asma S; Alamin, Maha A; Al-Mutairi, Nawal M; Alateeq, Raghad A. (2024). Renoprotective effect of liraglutide on diabetic nephropathy by modulation of Krüppel-like transcription factor 5 expression in rats.. The Journal of pharmacy and pharmacology, 76(12), 1563-1571. https://doi.org/10.1093/jpp/rgae127